نتائج البحث

Evaluation of the usefulness of plasma 4β‐hydroxycholesterol concentration normalized by 4α‐hydroxycholesterol for accurate CYP3A phenotyping.

• Authors : Oda, Ayako¹ (AUTHOR); Suzuki, Yosuke¹ (AUTHOR) y‐suzuki@my‐pharm.ac.jp; Sato, Haruki¹ (AUTHOR)

• Source: CTS: Clinical & Translational Science. Mar2024, Vol. 17 Issue 3, p1-11. 11p.

تفاصيل العنوان

Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.

• Authors : Ho YL; GSK, Collegeville, Pennsylvania, USA.; Gorycki P

Subjects: Ritonavir* ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Benzamides*

• Source: Clinical and translational science [Clin Transl Sci] 2024 Apr; Vol. 17 (4), pp. e13799.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Danazol increases the oral bioavailability of midazolam by inactivation of hepatic and intestinal CYP3A in rats.

• Authors : Fukuno, Shuhei¹ (AUTHOR); Nagai, Katsuhito¹ (AUTHOR); Kurotobi, Akemi¹ (AUTHOR)

• Source: Xenobiotica. May2023, Vol. 53 Issue 5, p421-428. 8p.

تفاصيل العنوان

A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.

• Authors : Tariq, Bilal¹ (AUTHOR); Ou, Ying C.² (AUTHOR); Stern, Jennifer C.² (AUTHOR)

• Source: Leukemia & Lymphoma. Feb2023, Vol. 64 Issue 2, p329-338. 10p.

تفاصيل العنوان

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

• Authors : Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.; Ramsden D

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/pharmacokinetics; Humans

• Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions.

• Authors : Loer, Helena Leonie Hanae¹ (AUTHOR); Feick, Denise¹ (AUTHOR); Rüdesheim, Simeon^1,2 (AUTHOR)

• Source: CPT: Pharmacometrics & Systems Pharmacology. May2023, Vol. 12 Issue 5, p724-738. 15p.

تفاصيل العنوان

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.

• Authors : Li, Xiaoyan¹ (AUTHOR) ; Shelton, Mark J² (AUTHOR); Wang, Jing¹ (AUTHOR)

• Source: Clinical Pharmacology in Drug Development. Oct2022, Vol. 11 Issue 10, p1165-1176. 12p.

تفاصيل العنوان

Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio.

• Authors : Mlugu, Eulambius M.^1,2 (AUTHOR); Minzi, Omary M.³ (AUTHOR); Kamuhabwa, Appolinary A. R.³ (AUTHOR)

Subjects: *CYTOCHROME P-450 CYP3A; *ENZYMES; *GAS chromatography/Mass spectrometry (GC-MS)SUB-Saharan Africa

• Source: International Journal of Molecular Sciences. Dec2022, Vol. 23 Issue 23, p15168. 11p.

تفاصيل العنوان

Protocol of the IntenSify‐Trial: An open‐label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

• Authors : Hohmann, Nicolas¹ (AUTHOR); Sprick, Martin Ronald^2,3 (AUTHOR); Pohl, Moritz⁴ (AUTHOR) ‐heidelberg.de

• Source: CTS: Clinical & Translational Science. Dec2023, Vol. 16 Issue 12, p2483-2493. 11p.

تفاصيل العنوان

Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?

• Authors : Yamazaki S; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, San Diego, California, USA.; Evers R

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics; Humans

• Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jan; Vol. 12 (1), pp. 8-12. Date of Electronic Publication: 2022 Nov 11.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان